ALS2CL

Across TCGA pan-cancer cohorts, ALS2CL Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ALS2CL data layer compared with 22 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher ALS2CL Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ALS2CL expression acts as an unfavorable survival marker.

UCS, LUAD, and KIRC are the cancer types where ALS2CL Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	OS	Median	All	0.102	0.688	<.001	36	view →
LUAD	OS	Median	II,III,IV	0.163	0.750	.001	29	view →
KIRC	OS	Median	All	0.182	0.805	.003	15	view →
SARC	DFS	Median	All	0.069	0.632	<.001	6	view →
ACC	DFS	Median	All	0.089	0.666	.017	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LIHC	OS	Median	III,IV	0.204	0.648	.030	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ALS2CL–UCS (OS)

Open the UCS breakdown →